Takeda Emerging Market Strategy Varies From Country To Country
This article was originally published in The Pink Sheet Daily
Takeda’s expansion into emerging markets using its Nycomed acquisition have positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China, but its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.
You may also be interested in...
Japan's largest drug maker confirms Nycomed deal, which will double its European sales, jumpstart its emerging markets presence and provide a 30% revenue boost as key drug Actos faces patent expiry.
Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.